section name header

Pronunciation

al-FYOO-zo-sin

Classifications

Therapeutic Classification: urinary tract antispasmodics

Pharmacologic Classification: peripherally acting antiadrenergics

Indications

REMS


Action

  • Selectively blocks alpha1-adrenergic receptors in the lower urinary tract to relax smooth muscle in the bladder neck and prostate.
Therapeutic effects:
  • Increased urine flow and decreased symptoms of BPH.

Pharmacokinetics

Absorption: 49% absorbed following oral administration; food enhances absorption.

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized by the liver via the CYP3A4 isoenzyme system; 11% excreted unchanged in urine.

Half-Life: 10 hr.

Time/Action Profile

ROUTEONSETPEAKDURATION
PO-ERwithin hr8 hr24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: postural hypotension

Derm: TOXIC EPIDERMAL NECROLYSIS

EENT: intraoperative floppy iris syndrome

GI: abdominal pain, constipation, dyspepsia, nausea

GU: erectile dysfunction, priapism

Hemat: thrombocytopenia

Neuro: dizziness, fatigue, headache

Resp: bronchitis, pharyngitis, sinusitis

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Uroxatral

Canadian Brand Names

Xatral